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Time to Think Beyond Risk Prediction?*Khurram Nasir, MD, MPHyzxk“I f we produce food that no one eats, we needto consider different crops.” (1)
Hardly any other topic than the role of cardio-
vascular (CV) imaging in how we manage our pa-
tients generates passionate debate among health
care stakeholders. Despite this, CV imaging con-
tinues to play a major role in our clinical decision-
making processes and is performed in more than 10
million patients each year for enhanced risk predic-
tion and initiation of targeted therapies with ulti-
mate goals of improving outcomes (2). Among the
spectrum of choices for CV imaging, established
modalities such as invasive angiography, echocardi-
ography, and myocardial perfusion imaging are
deeply embedded in our standard of care processes,
especially for those with suspected and symptomatic
CV disease. Due to the consideration of additional
costs and potential undesired downstream implica-
tions, there is apprehension with regard to expand-
ing the horizon for newer modalities. Adding any
new CV imaging test in our clinical practice faces a
much more stringent task than its predecessors,
amidst demands of demonstrating value speciﬁcally
in the form of improved outcomes. It is worthwhile
to note that although critically considering these
criteria, evidence is limited even for these estab-
lished CV imaging tests; however, this debate is
unlikely to change the burden of proof asked of
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dividuals, considering the large population that it
can affect, potential initial costs, lower risk of an
adverse event (that can potentially be prevented) in
the short term, and the lack of clear-cut incentives
to project savings in the long term by our current
complicated landscape of a mixed form of private
payers and governmental agencies. Coronary artery
calcium (CAC) testing is a prime example of these
challenges. Despite the: 1) presence of an unprece-
dented amount of evidence for superior risk pre-
diction; 2) potential to affect management decisions
and behavior; and 3) recent demonstration of being
cost-effective from a societal perspective, the use of
CAC testing remains to be limited due to the lack of
consensus on guidelines and continued resistance by
payers to reimburse costs (3).
Discussions on the appropriate future roles of
emerging CV imaging modalities can be better facili-
tated when examined in the context of our health
care constraints considered above. Fluorodeox-
yglucose positron emission tomography (FDG-PET)
imaging with its ability to capture the differential rate
of tissue glycolysis is an established tool in clinical
oncology for estimating tumor activity and for
detection of occult infection in inﬂamed tissues. The
potential utility of FDG-PET imaging to complement
current CV imaging tools in humans rapidly pro-
gressed from observation of heightened PET activity
in patients with vasculitis in 1987 to a point in 2001
where FDG uptake in the great vessels was clearly
linked to atherosclerosis (4). In the past decade, the
role of FDG-PET/computed tomography (CT) in
demonstrating the therapeutic antiatherosclerotic ef-
ﬁcacy of proven treatments as well evaluating novel
pharmacological agents for these purposes has added
signiﬁcant value to drug development processes. In
recent years, investigators pointed out that arterial
inﬂammation noted on routine FDG-PET CT scans
performed in active cancer patients and survivors can
enhance our ability to predict subsequent CV events in
this vulnerable population (5).
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958In the current study in this issue of iJACC, Moon
et al. (6) demonstrated that the prognostic value
derived from measuring carotid arterial FDG extends
to individuals free of established cancer or CV disease.
The study investigators critically assessed the value of
measuring the average FDG uptake of both carotid ar-
teries normalized to the venous blood in nearly 1,000
asymptomatic individuals who underwent PET/CT for
cancer screening. Overall, this was a low-risk popula-
tion, with only 19 events (1.7%) noted in amean follow-
up of 4 years, notably half of them were anginal rather
than atherothrombotic in nature. Two-thirds of events
occurred in one-third of participants with the highest
FDG uptake in carotid vessels. Surprisingly, as high-
lighted in Figure 1, even among those with the highest
vessel wall FDG uptake, which may indicate plaque
vulnerability, no events were noted in the ﬁrst 2 years,
with the majority of them occurring 4 years into the
follow-up. This observation slightly conﬂicts with
ﬁndings from Figuero et al. (7) who noted that those
with elevated large arterial inﬂammation signals on
PET were more likely to experience near-term CV dis-
ease. Irrespectively, robust statistical metrics used in
the study demonstrated independent predictive value
from arterial wall PET activity measurement beyond
traditional risk factors and carotid intima-media
thickness, an established surrogate for atheroscle-
rotic disease burden.
These encouraging results add to the increasing
recognition of potential predictive value of FDG-PET
detection of inﬂammation for future adverse cardiac
events. However, one needs to ask what is this added
information worth? Would the results inﬂuence our
stakeholders to adopt FDG-PET for risk assessment?
Despite the promising results, the translational po-
tential of FDG-PET for this speciﬁc purpose in an
asymptomatic population, in my humble view, is
limited. Among many considerations, one needs to
take into account the signiﬁcant cost, major radiation
exposure, and lack of comparative data with more
established imaging risk stratiﬁcation tools such as
CAC testing. Future research in this area needs to
consider these issues in study designs. However, are
there any clinical scenarios well suited for predicting
CV risk with FDG-PET testing? Based on the current
and recent studies, we are optimistic that signiﬁcant
information can be derived if additional measure-
ment of arterial activity becomes a standard of care of
those in whom FDG-PET imaging is routinely per-
formed. This is a situation where clear value is added
in how we can manage our patients without addi-
tional costs or radiation exposure.Considering our stakeholders’ demand for an
accelerated drive toward value-based health care de-
livery, investigations that does not seek opportunities
beyond mere risk prediction will unfortunately have
limited impact. So how do we navigate these chal-
lenges? For guidance, we need not look beyond
the fantastic blueprint provided by the editors of
iJACC, reminding us that CV imaging research needs
concerted efforts to move beyond assessment of ac-
curacy and prediction (2). These recommendations
persuasively highlight practical steps for developing
deﬁnitive evidence for any given modality with goals
to improve “end results.” Encouragingly, comparative
effectiveness research goals in the current era are not
narrowly focused on realizing a reduction in clinical
events, but also include additional worthy targets such
as clarifying the role of CV imaging in the optimal
management protocols for physicians, appropriate
resource allocation for providers, and, more impor-
tantly, facilitating informed choices for our patients.
The challenges highlighted by a lack of clear down-
stream implications as noted in the current study are
not limited to this speciﬁc situation or imaging mo-
dality. Each year, hundreds of CV imaging research
studies continue to frame the question “does it
improve risk prediction?” despite the fact that this
knowledge will less likely cater to the broader health
care needs. This singular approach in the past may
have limited our ability to unlock the true value of CV
imaging by not focusing on relevant research
addressing ourmore urgent needs. This is notmeant to
discourage risk prediction research, but to redirect our
energies so that we can place a higher value on evi-
dence that needs to be generated. We acknowledge
that these prediction speciﬁc investigations have
played a pivotal role in clarifying pathophysiological
diseasemechanisms, disease speciﬁc associations, and
risk among different clusters; however, it is worth
contemplatingwhether it is time to shift our goals. This
will not be an easy task andwill require amajor cultural
shift. More importantly, we will have to rely on stake-
holder consensus for deﬁning ‘rational’ research that
will cater to their speciﬁc needs. The entire CV imaging
investigation community will be better served if we
demand a greater return of investment by asking, “Is
there anyone who would do something differently
because of the results of the research?” (1).
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